e at -20C	PHLDA3 Antibody			
Store (Orders:	877-616-CELL (2355) orders@cellsignal.com	
)4		Support:	877-678-TECH (8324)	
4294		Web:	info@cellsignal.com cellsignal.com	
#		3 Trask Lane Danvers Ma	ssachusetts 01923 USA	

For Research Use Only. Not for Use in Diagnostic Procedures.

Reacti H M R		MW (kDa): 15	Source: Rabbit	UniProt ID: #Q9Y5J5	Entrez-Gene lo 23612		
Product Usage Information	Application Western Blotting		Dilution 1:1000				
Storage	- Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.						
Specificity / Sensitivity	PHLDA3 Antibody detects endogenous level of total PHLDA3 protein.						
Source / Purification	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PHLDA3 protein. Antibodies are purified by protein A and peptide affinity chromatography.						
Background	Pleckstrin homology-like domain family A member 3 (PHLDA3) is one of three relatively small, similar proteins that share a common pleckstrin homology (PH) domain. Expression of PHLDA3 and the related PHLDA1 occurs in several fetal and adult tissues, in contrast to the more restricted expression of PHLDA2 seen in mouse tissues (1). PHLDA3 is one of several proteins induced following treatment of tumor cells with cisplatin, an anti-cancer drug that cross-links DNA and promotes apoptosis through activation of the tumor suppressor p53 (2). Additional evidence that PHLDA3 is involved in promoting apoptosis through p53 came from a study examining the opposing effects of p53 and Akt in tumor development. Tumor suppressor p53 binds the PHLDA3 promoter to induce transcription. Induced overexpression of PHLDA3 increases apoptosis while deletion of PHLDA3 results in increased Akt activity and a reduction in p53-mediated apoptosis. PHLDA3 appears to compete with the PH domain of Akt, preventing Akt activation and promotion of Akt-induced cell survival pathways (3).						
Background References	1. Frank, D. et al. (1999 2. Kerley-Hamilton, J.S. 3. Kawase, T. et al. (200	et al. (2005) Onco	gene 24, 6090-100.				
Species Reactivity	Species reactivity is dete	ermined by testing i	n at least one appro	wed application (e.g., we	estern blot).		
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Cross-Reactivity Key		B: bovine Dg: dog	r Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse cies expected				
Trademarks and Patents			of Cell Signaling Technology, Inc. heir respective owners. Visit cellsignal.com/trademarks for more				
Limited Uses	following terms apply to conditions that are in add	pt as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the ving terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and tions that are in addition to, or different from, those contained herein, unless separately accepted in g by a legally authorized representative of CST, are rejected and are of no force or effect.					
	Products are labeled with approved, cleared, or lice Customer shall not use a that conflicts with its labe end-user and solely for r	ensed by the FDA c any Product for any eling statement. Pro	or other regulatory for diagnostic or thera oducts sold or licens	preign or domestic entity peutic purpose, or other ed by CST are provided	r, for any purpose. wise in any manner I for Customer as the		

PHLDA3 Antibody (#4294) Datasheet Without Images Cell Signaling Technology

therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.